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ORIGINAL ARTICLE 
Assessing referrals to urology outreach in  
cases of acute urinary retention 
Arthur Curmi,  Jonathan Debattista, Gerald Busuttil,  Kelvin Holmes, Keith Pace, John Sciberras
INTRODUCTION 
Acute Urinary Retention (AUR) is the sudden and often painful 
inability to pass urine characterised by a palpable or percussible 
bladder.  It constitutes 45% of all lower urinary tract consultations 
and is encountered in different medical specialties. A local guideline 
was set up to delineate the management of acute urinary retention 
(AUR) in July 2018. It describes the clinical features, investigations 
and treatment required according to the severity of the episode.  The 
aim of this audit is to assess the demographics of patients making use 
of the Urology Outreach Unit (cases of AUR), and trends in 
investigations done, treatment chosen and outcomes on such 
patients. 
METHOD 
 All patients older than 16 years of age who presented with AUR 
between March 2018 and September 2018 were included.  Data was 
obtained from Urology TWOC forms and corroborated with the 
hospital online system. 
RESULTS 
89 (37.6%) of the referrals were done from Accident and Emergency 
Department (A&E), and 86 (36.3%) were referred from Urology firms.  
Urinalysis and Microscopy was sent in 45.1% of cases. Renal profile 
(serum) was taken in 70.5% of cases.  The most commonly used 
catheter type used was silicone (89.6%).  Catheter size of 16F was 
used in 83.8% of the cases.  The average days spent with the catheter 
in situ was 11.7 days.  The average attempts at TWOC was 1.1 times 
(max of 3).  83.5% of patients were then advised to continue their 
medical therapy with appropriate follow up following a successful 
TWOC.  The rest were scheduled for a repeat TWOC (13.1%), fitted 
with a long-term catheter (1.69%), advised regarding self-
intermittent catheterisation (1.27%), or referred for TURP (0.42%). 
CONCLUSION 
This audit shows variable compliance to clinical guidelines.  An active 
role of the clinician in the management and treatment of AUR might 
improve treatment and reduce the risk of further episodes of AUR. 
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BACKGROUND 
A local guideline was set up to delineate the 
management of acute urinary retention (AUR) 
in July 2018. It describes the clinical features, 
investigations and treatment required 
according to the severity of the episode. For 
patients that are not admitted to hospital, or 
those that will be admitted, but will be 
discharged before an in-hospital trial without 
catheter (TWOC), a referral to Urology 
Outreach is to be organized. Key steps in the 
management of AUR are to be documented on 
the referral sheet to Urology Outreach, to 
ensure proper continuity of care. The aim of 
this audit is to assess the demographics of 
patients making use of the Urology Outreach 
Unit (cases of AUR), and trends in 
investigations done, treatment chosen and 
outcomes on such patients. 
METHODOLOGY 
Data was primarily obtained from Urology 
Outreach records. This was corroborated with 
data on hospital online systems.  The audit 
period was from March 2018 to September 
2018. 
Inclusion criteria were include adults older the 
16 years of age and at least 1 episode of AUR. 
RESULTS 
Demographics: 237 entries were included in 
the audit, fitting the inclusion criteria above. 
218 (92%) were male. Minimum age was 38 
years, maximum of 93 years (average of 71 
years).  
Referral Source: The referrals were sent from 
various medical facilities. 89 (37.6%) were 
done from Accident and Emergency 
Department (A&E), and 86 (36.3%) were 
referred from Urology firms (Figure 1).  
Characteristics of the episode: The cases were 
split evenly between painful AUR (118) and 
painless AUR (119). The residual volume was 
recorded on 71.3% of cases. Minimum residual 
volume was 135mL, and the maximum was 
3000mL (average: 684.5mL). 16.9% of these 
patients were admitted; with length of stay 
varying from 1 day up to 23 days (average of 5 
days).  
Investigations: Urinalysis and Microscopy was 
sent in 45.1% of cases. Renal profile (serum) 
was taken in 70.5% of cases. Of note, the eGFR 
ranges were 8 up to 149 (average 74.1), with 
50.2% of cases having an eGFR of more than 
60. 
Treatment: 222 entries (93.7%) had 
documented the insertion of a catheter. The 
catheter-type used was silicone (89.6%) 
(Figure 2). Of the total 222 catheters, 83.8% 
were 16F in size.  With regards to medical 
treatment, 27.4% were not on any treatment 
prior to the event, and were not started on any 
treatment either. 48.5% were started on 
treatment. Documented changes in treatment 
can be seen in Figure 3 
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TWOC: The average days spent with the 
catheter in situ was 11.7 days (maximum 
documented of 49 days, and a minimum of 2). 
The average attempts at TWOC was 1.1 times 
(max of 3). The procedure was successful 
83.5% of the time. The post-voiding residual 
(PVR) volumes ranged from 0mL up to 
1000mL, the average being 154.97mL.  In those 
TWOCs that were successful, the maximum 
PVR value was 690mL (average 97.82mL), and 
in those TWOCs that were not successful, the 
minimum was 150mL, the maximum was 
1000mL, and the average was 486.31mL. The 
catheter residual was also documented; the 
average amount was 544.53mL (maximum of 
1200mL, minimum of 250mL).  
Outcome: 83.5% of patients (corresponding to 
successful TWOC cases) were then advised to 
continue their medical therapy with 
appropriate follow up. The remaining cases 
were either scheduled for a repeat TWOC 
(13.1%), fitted with a long-term catheter 
(1.69%), advised regarding self-intermittent 
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catheterisation (1.27%), and referred for TURP 
(0.42%). 
DISCUSSION 
Acute Urinary Retention (AUR) is the sudden 
and often painful inability to pass urine 
characterised by a palpable or percussible 
bladder.  Chronic Urinary Retention (CUR), on 
the other hand, is painless retention 
associated with high residual volumes after 
voiding.  AUR is the most common urological 
emergency typically occurring in men between 
60 and 80 years of age.1  It constitutes 45% of 
all lower urinary tract consultations and is 
encountered in different medical specialties.2  
As expected the majority of our referrals were 
made from the emergency department 
(37.6%), urology (36.3%) and other surgical 
firms (16.9%).  According to research, 10% of 
men over 70s and nearly a third over 80s will 
develop AUR.3 
Obstruction occurring at or distal to the neck 
of the bladder may cause retention of urine.  
Obstruction may occur within the lower 
urinary tract itself (bladder stones, urethral 
strictures, prostate enlargement) or due to 
external compression of the bladder neck from 
a gastrointestinal or uterine mass.  The most 
common cause in males is benign prostatic 
hyperplasia (BPH) with risk factors including 
advancing age, African American origin, 
increased body habitus, diabetes, alcohol 
consumption and a sedentary lifestyle.1  
Flaccidity or detrusor muscle failure can also 
cause incomplete bladder emptying leading to 
chronic urinary retention.1  Other causes of 
AUR can be infective, inflammatory, 
pharmacologic or neurologic in origin.  
Thorough history taking and physical 
examination will often identify the underling 
etiology. 
 
The diagnosis of AUR is aided by bladder 
ultrasonography. A volume equal or greater 
than 300mls in a patient who is unable to 
empty the bladder suggests retention.4  Body 
habitus, previous surgery, scarring or tissue 
edema may give inaccurate bladder volumes.1  
Placement of a urethral catheter may, 
therefore, be required.  It is considered to be 
the gold standard for measuring the post-
voiding residual.5  The amount of urine drained 
in the first 15 minutes after catheter insertion 
should be measured and recorded.   In our case, 
the residual volume was recorded on 71.3% of 
the sheets.  Urine should be tested for 
infection, and biochemistries evaluated to 
check for renal dysfunction and electrolyte 
imbalances.6  Urinalysis was sent in 45.1% of 
cases, while serum renal profile was taken in 
70.5% of cases. 
Management of AUR should involve 
immediate and complete decompression of 
the urinary bladder through catheterisation in 
order to relieve patient discomfort.7  The most 
commonly used catheter type was silicone 
(89.6%) followed by latex (5.4%).  Silicone has 
a longer half-life so tends to be preferred for 
long-term use.  First line urethral catheter 
should be 16 to 18 French in size.  83.8% of our 
cases had a 16 French catheter inserted. 
Smaller catheter sizes of 10 to 12 French may 
be used in cases involving a stricture.  If 
urethral catheterisation fails, the urologist 
must be involved for consideration of 
catheterisation under vision, or suprapubic 
catheterisation.  In circumstances where a 
urologist is not readily available, suprapubic 
aspiration via a needle under ultrasound 
guidance may be attempted.  
Contraindications to urethral catheterisation 
include recent urologic surgery such as 
urethral reconstruction and radical 
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prostatectomy.  These group of patients 
should undergo suprapubic catheterisation.8 
After the initial management patients are 
either admitted or discharged home and seen 
as outpatients.  Patients with normal renal 
function and no significant comorbidities can 
be safely discharged home following 
catheterisation with a date for a later TWOC.9  
In our audit, 188 patients had an eGFR below 
60 but only 40 patients (16.9%) were admitted 
to hospital. This might be due to pre-existing 
renal disease, and not new-onset renal 
dysfunction.  
Although there is no general consensus when 
TWOC should be performed, in our audit 
removal of catheter was performed on day 11 
on average.  In the UK the majority of patients 
have their catheter removed on day 2 while in 
France TWOC is usually performed on day 3.10  
Some reports show that a prolonged duration 
of catheterization increased the chances of a 
successful TWOC.11  Catheterisation for more 
than 3 days was actually associated with higher 
successful TWOC rates.  However, prolonged 
catheterisation is associated with higher risk of 
complications including haematuria, urosepsis 
and urine leak so efforts should be made to 
reduce the duration of a urethral catheter.12  
This not only reduces comorbidities but also 
cuts down on healthcare costs.  Reports state 
that there is a greater chance of successful 
TWOC if the patient is under 65 years of age, 
detrusor pressure is more than 35cm water, 
volume of urine drained is less than 1 litre at 
catheterisation and precipitating event is 
identified.13    A TWOC is considered successful 
if the patient voids more than 100mls within 6 
hours after removal of urinary catheter and 
the post-voiding residual volume is less than 
200mls.14  If  removal of catheter is successful, 
patient needs follow up of lower urinary tract 
symptoms and treatment review. 
Once the catheter is removed some patients 
will fail to pass urine normally and require re-
catheterisation.  These individuals may be 
managed by use of an indwelling catheter, self-
intermittent catheterisation or considered for 
prostate surgery. Hence, measures to increase 
the rate of successful TWOCs are vital.  The 
limited available research evidence implies 
that alpha blockers increase the rate of 
successful TWOCs.  Data was statistically 
significant for tamsulosin, alfuzosin and 
silodosin.13 They work by decreasing the 
smooth muscle tone of the prostate and 
increasing urinary flow with improvement of 
urinary symptoms.  Tamsulosin which is given 
as 400mcg daily was the alpha blocker of 
choice (49.7%) while alfuzosin which is given as 
10mg daily was used in 3.5% of the cases.  
Silodosin 8mg daily was not used at all.  A 
combination of Tamsulosin and Finasteride (a 
5-α-reductase inhibitor) was the second most 
preferred choice with 37.4% of cases.  A 
combination therapy is usually preferred in 
men with very large prostates to maximize the 
prevention of further episodes of AUR.15 
The number of TWOCs depend on patient 
characteristics, such as fitness to undergo 
surgery (like TURP) and also patient 
preference.  In our audit 3 patients were 
referred for a third TWOC while another 2 
patients were referred for a 4th TWOC.  
Surgical intervention is considered to be a last 
resort in the treatment of AUR. In males with 
BPH who fail a second TWOC, transurethral 
resection of the prostate (TURP) reduces AUR 
by 85 to 90 percent.16 Surgery should be 
carried out until at least 30 days following the 
episode of AUR, to minimize the risk of surgical 
complications.17  Out of 237 patients, only one 
(0.42%) was referred for TURP.   This number 
could be an underrepresentation of the actual 
number of TURP referrals, since the decision 
8
Malta Medical Journal     Volume 33 Issue 01 2021           
for TURP is often made at a later stage at 
outpatients after a series of failed TWOCs.   
RECOMMENDATIONS 
Clinicians should perform an appropriate 
evaluation.  A urine sample and a renal profile 
should be taken in all cases of AUR and pre and 
post voiding residual checked with a bladder 
scanner.  Moreover the practitioner must make 
sure that the residual is recorded 
appropriately in the TWOC form provided 
after insertion of the urinary.  Intermittent 
self-catheterisation is another option.  
Although this can be difficult to employ from 
the emergency setting it can be used in 
patients who fail a TWOC whilst they are 
waiting for surgery.  Adequate patient 
education about catheter care and importance 
of anti-sepsis should be provided.  Involving 
patients in the decision-making process can 
also promote guideline use.  Nurse should be 
aware about the contraindications of catheter 
insertion and must be able to recognize them. 
Clinicians need to be knowledgeable on how to 
perform suprapubic aspiration in cased where 
patient is in severe distress and urologist is not 
readily available.  Coordination between the 
different members of the health care team is 
needed to improved patient outcomes. 
CONCLUSION 
This audit shows variable compliance to clinical 
guidelines. Hence, improvement both in the 
implementation and adherence to such 
guidelines is important as it improves the 
standard of care. An active role of the clinician 
in the management and treatment of AUR 
might improve treatment and reduce the risk 
of further episodes of AUR. 
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